|
|
Knowledge is Everything
Get the facts about colorectal cancer
- Colorectal cancer (CRC) is the second leading cause of cancer-related death in the US.1
- One in 18 people will develop CRC.2
- In 2006, approximately 147,000 people will be diagnosed with CRC, and 55,000 will die from the disease.
- Less than 50% of Americans aged 50 and older are routinely screened for CRC.3
Colorectal cancer is highly preventable through early detection with proper screening.
If you are over 50 or have a family history of colorectal cancer, see your doctor to schedule a colonoscopy.
Colorectal Cancer Screening Information (PDF 411KB)
Preventing colon cancer starts with knowledge. Visit your local Walgreen Pharmacy in March to learn more.
References:
Get Adobe Acrobat Reader
COLAZAL® (balsalazide disodium) Capsules 750 mg are indicated for the treatment of mildly to moderately active Ulcerative Colitis in patients 5 years of age and older.
COLAZAL does not relieve symptoms in all patients; your patients' results may vary. In four well-controlled clinical trials, patients receiving a COLAZAL dose of 6.75g/day most frequently reported the following events
(reporting frequency > 3%): headache (8%), abdominal pain (6%), diarrhea (5%), nausea (5%), vomiting (4%), respiratory infection (4%), and arthralgia (4%). Withdrawal from therapy due to adverse events was comparable to
placebo. In the pediatric trial, patients most frequently reported the following adverse events: headache (15%), abdominal pain upper (13%), abdominal pain (12%), vomiting (10%), diarrhea (9%), colitis ulcerative (6%),
nasopharyngitis (6%) and, pyrexia (6%). COLAZAL is contraindicated in patients with a hypersensitivity to salicylates or the components of COLAZAL capsules or balsalazide metabolites. The safety and effectiveness of
COLAZAL beyond 8 weeks in children (ages 5-17 years) and 12 weeks in adults have not been established.
Consult with your physician to see if this product is right for you.
For complete Prescribing Information, please click here.
|
|